Aktivitas antitrombin sing kurang ora kanthi otomatis ateges defisiensi bawaan: gumpalan getih akut, heparin, penyakit abot utawa kelangan protein bisa nyuda aktivitasé sauntara. Klinisi ngonfirmasi kelainan sing tetep ana kanthi tes aktivitas ing wektu sing cocog, kadhangkala tes antigen, lan rencana laboratorium sing nggatekake obat—asring sawisé 3 sasi pisanan perawatan gumpalan getih.
Pokok-pokok penting
- Rentang referensi: Aktivitas antitrombin wong diwasa lumrahé ana ing kisaran 80–120%; gunakna rentang sing kacithak ing laporan panjenengan.
- Siji asil kurang: Aktivitas 65% nalika ana gumpalan getih anyar utawa perawatan heparin ora bisa netepaké defisiensi antitrombin bawaan.
- Wektu kanggo ngulang: British Society for Haematology nyaranaké supaya defisiensi antikoagulan alami dites mung sawisé 3 sasi antikoagulasi kanggo trombosis akut.
- Aktivitas mbandhingaké karo antigen: Defisiensi tipe I biasané nyuda loro pangukuran; defisiensi tipe II nyuda fungsi, déné antigen bisa tetep normal.
- Gangguan saka obat: Apixaban, rivaroxaban lan edoxaban bisa nuwuhaké asil aktivitas palsu sing luwih dhuwur ing tes adhedhasar faktor Xa; dabigatran bisa nuwuhaké asil kaya mangkono ing tes adhedhasar trombin.
- Kelangan protein: Насанд хүрэгчдийн нефротик хүрээний протеинури нь уламжлалт байдлаар 24 цагт дор хаяж 3.5 g байдаг бөгөөд олдмол антитромбины бууралтад нөлөөлж болно.
- Гэр бүлийн үнэлгээ: Батлагдсан гетерозигот удамшлын дутагдалтай үед хүүхэд бүр холбогдох хувилбарыг өвлөх магадлал 50% байдаг—цусны бүлэн үүсэх нь 50% гарцаагүй гэсэн үг биш.
- Keamanan obat: Эм бичиж өгсөн эмчийн тань хувь хүнд тохирсон төлөвлөгөөгүйгээр лабораторийн шинжилгээний үр дүнг илүү тодорхой болгохын тулд антикоагулянт эмчилгээг хэзээ ч зогсоож болохгүй.
Apa tegesé aktivitas antitrombin sing kurang?
Антитромбины идэвхжил бага гэдэг нь лабораторийн шинжилгээгээр хүлээгдэж байснаас бага антикоагулянт үйл ажиллагаа илэрснийг хэлнэ; энэ нь дангаараа шалтгааныг тогтоохгүй. Насанд хүрэгчдийн лабораторийн доод хязгаараас—ихэвчлэн ойролцоогоор 40%—бага үр дүн нь удамшлын дутагдал, түр зуурын зарцуулалт, нийлэгжил буурах, уураг алдагдах эсвэл шинжилгээний асуудлыг илтгэж болно.
Антитромбин нь тромбин буюу IIa фактор, Xa фактор зэрэг ферментийг дарангуйлж, бүлэгнэлтийг хязгаарладаг. 36% идэвхийн үр дүн нь шинжилгээний калибровкын стандартад харьцуулсан үзүүлэлтийг илэрхийлнэ; цусны эргэлт тань 36% хамгаалагдсан эсвэл цусны бүлэн үүсэх магадлал тань 51% гэсэн үг биш.
Цус бүлэгнэлтийн ердийн шинжилгээ хэвийн байх нь антитромбины дутагдлыг үгүйсгэхгүй. Учир нь PT болон aPTT нь удамшлын бүлэн үүсэх хандлага бүрийг илрүүлэх скрининг шинжилгээ биш. Бидний тайлбар цус бүлэгнэлтийн шинжилгээний хэвийн үзүүлэлтийн хязгаарлалт эдгээр асуултыг ялгахад тусална: бүлэгнэлтийн хугацаа уртассан эсэх, мөн байгалийн тодорхой антикоагулянт хэвийн үйлчилж байгаа эсэх нь 2 өөр үнэлгээ юм.
Kantesti нь хиймэл оюун ухаантай цусны шинжилгээний анализатор бөгөөд идэвхийн хувийг эмийн түүх болон холбогдох лабораторийн үр дүнтэй хамтатган авч үзэхэд тусалдаг; нэг хэвийн бус тэмдэглэгээг онош гэж үздэггүй. Манай компанийн тухай мэдээлэл ба зорилго энэ үүргийг тайлбарлана; удамшлын дутагдлыг батлахын тулд эмчийн удирдлага дор шинжилгээ хийх шаардлагатай бөгөөд яаралтай шинж тэмдгийг хиймэл оюун ухааны аливаа тайлбараас үл хамааран үнэлэх ёстой.
Rentang aktivitas antitrombin pira sing dianggep kurang?
Насанд хүрэгчдийн антитромбины идэвхжил лавлах хэмжээ нь ихэвчлэн ойролцоогоор 80–110% байдаг ч зарим лаборатори 80–130% эсвэл өөр баталгаажуулсан хязгаар хэрэглэдэг. Иймээс 75% идэвхжил нь ихэвчлэн доод хязгаарт ойр бага үзүүлэлт боловч 75% ч бай, өөр ямар нэг дан босго утга ч бай удамшлын дутагдлыг нотлохгүй, яаралтай эмчилгээ шаардлагатай эсэхийг тогтоохгүй.
Гетерозигот удамшлын антитромбины дутагдалтай олон хүний идэвхжил ойролцоогоор 40–70% байдаг ч олдмол эмгэгүүд ижил утга үүсгэж болно. Харин зарим удамшлын хувилбар идэвхжилийг харьцангуй бага бууруулдаг эсвэл зарим шинжилгээгээр илрэхгүй өнгөрдөг; эмч нар бууралтын хэмжээг давтан шинжилгээний үр дүнтэй хамтатган тайлбарладаг бөгөөд дангаар нь генетикийн онцлог гэж үздэггүй.
Нас нь тайлбарт ихээхэн нөлөөлдөг: хугацаандаа төрсөн эрүүл нярайд антитромбины идэвхжил насанд хүрэгчдийнхтэй харьцуулахад ойролцоогоор 40–60% байж болох бөгөөд нярай үед түвшин нэмэгддэг. Дутуу төрөлт нэмэлт хэлбэлзэл үүсгэдэг, мөн жирэмсний хожуу үе эсвэл төрсний дараах эхний үед ч үр дүнд нөлөөлж болно; насанд хүрэгчдийн 40%-ийн доод хязгаарыг ялгалгүй хэрэглэх нь төөрөгдүүлсэн оношийн нэршилд хүргэж болзошгүй.
Илэрхий таамаг төдий жишээ авбал, идэвхжил нь 78% бөгөөд өмнө нь цусны бүлэн үүсэж байгаагүй, бусдаар эрүүл насанд хүрсэн хүний үнэлгээ хүнд сепсистэй үед идэвхжил нь 42% гарсан насанд хүрсэн хүнийхээс өөр байна. Хоёр тайланд хоёуланд нь ижил бага үзүүлэлтийн тэмдэглэгээ гарч болох ч бидний asil laboratorium sing ora ana ing rentang лавлах хязгаар нь оношилгоо эсвэл эмчилгээний босготой адил зүйл биш гэдгийг тайлбарлана.
| Tingkat | Rentang | Tegesé |
|---|---|---|
| Насанд хүрэгчдийн түгээмэл хэмжээ | Ойролцоогоор 80–110% | Ихэвчлэн хэвийн хэмжээнд байдаг ч тухайн лабораторийн өөрийн хэмжээ болон шинжилгээний мэдрэг чанарыг нэн тэргүүнд харгалзана. |
| Хил орчмын бууралт | 70–79% | Asring mbutuhake tinjauan konteks lan konfirmasi ing wektu sing cocog; dudu diagnosis. |
| Pangurangan sing cetha | 50–69% | Cocog karo defisiensi bawaan utawa sing dipikolehi; aktivitas waé ora bisa mbedakake loro-loroné. |
| Nyuda banget | Ing ngisor 50% | Mbutuhake tinjauan klinis, utamané nalika lara utawa ngalami trombosis; persentase waé ora netepake kahanan darurat. |
Antigen antitrombin mbandhingaké karo aktivitas: apa bedané?
An tes aktivitas antitrombin ngukur sepira efektif protein nyegah enzim koagulasi, déné antigen antitrombin ngukur sepira akèhé protein sing ana. Defisiensi bawaan tipe I umume nyuda loro-loroné; tipe II umume nyuda aktivitas sanajan konsentrasi antigen relatif normal, mula loro tes iki nglengkapi siji lan sijiné, dudu bisa diijolaké.
Akèh-akèhé metode aktivitas rutin yaiku uji kromogenik: laboratorium nambahaké enzim lan ngukur pira sing isih ana sawisé antitrombin nyegah enzim kasebut. Rekomendasi laboratorium ISTH nyaranaké tes aktivitas luwih dhisik, banjur pangukuran antigen nalika aktivitasé cendhèk, kanthi nyingkiraké panyebab sing dipikolehi lan gangguan uji sadurungé klasifikasi (Van Cott et al., 2020).
Coba delengen 2 profil hipotetis saka tes ulang ing kahanan sing trep: aktivitas 52% kanthi antigen 49% ndhukung pola kuantitatif, déné aktivitas 52% kanthi antigen 101% ndhukung pola kualitatif. Conto iki dudu rumus diagnostik, amarga penyakit sing dipikolehi bisa nyuda loro pangukuran lan uji antigen ora njlentrehaké apa asil fungsionalé kleru merga obat.
Defisiensi tipe II nyakup kelainan situs réaktif, situs pengikatan heparin lan kelainan fungsional liyané; pilihan uji bisa mengaruhi sepira gampangé varian dideteksi. Mula, panjlentrehan Kantesti mbedakaké cacah saka kinerja, béda sing uga digambaraké déning tingkat protein lawan fungsi ing uji inhibitor esterase C1—nanging kuwi protein sing béda kanthi akibat klinis sing béda.
Apa gumpalan getih akut bisa nyuda antitrombin sauntara?
Trombosis akut bisa nyuda aktivitas antitrombin kanggo sawatara wektu amarga konsumsi, utamané yèn diiringi penyakit, prosedur utawa pengaruh perawatan. Mula, angka kayata 58% nalika lagi didiagnosis trombosis vena jero ora bisa dipercaya kanggo mbedakaké defisiensi dhasar bawaan saka pangurangan sing disebabaké kedadéan saiki.
British Society for Haematology nyaranaké supaya defisiensi antikoagulan alami dites mung sawisé 3 sasi terapi antikoagulan kanggo trombosis akut, amarga asil awal ora bisa dipercaya lan arang ngowahi tata laksana langsung (Arachchillage et al., 2022). Iki rekomendasi bab wektu diagnosis, dudu prentah kanggo nundha perawatan tumrap gumpalan sing dicurigani utawa mandheg ngonsumsi antikoagulan nalika tekan sasi kaping 3.
Pasien hipotetis nduwèni aktivitas 61% nalika ngalami embolisme pulmoner lan 96% sawisé mari, kanthi nggunakake uji sing cocog. Owah-owahan kuwi ndhukung pangurangan sementara, nanging mbandhingaké 2 persentase waé isih durung pepak kajaba dhokter ngerti apa heparin, antikoagulan oral langsung, produk pangganti utawa metode laboratorium sing béda mengaruhi salah siji pangukuran.
D-dimer njawab pitakonan sing béda: iki nuduhaké pambentukan lan pemecahan fibrin, dudu cacah antitrombin utawa status bawaan. Artikel kita bab tes pembekuan getih lan D-dimer nerangaké apa sebabé D-dimer dhuwur lan aktivitas cendhèk bisa kedadéan bebarengan sajrone 1 kedadéan akut tanpa mbuktekaké yèn antitrombin cendhèk kuwi sing njalari gumpalan.
Yagéné perawatan heparin bisa nyuda aktivitas antitrombin?
Heparin bisa nyuda antitrombin sing sirkulasi sajrone perawatan, mula asil cendhèk sing dijupuk nalika nampa heparin ora difraksinasi utawa heparin bobot molekul cendhèk bisa nuduhaké pangurangan sing dipikolehi. Heparin uga gumantung marang antitrombin kanggo akèh-akèhé efek antikoagulané; mula, aktivitas 50% sajrone perawatan bisa nuwuhaké pitakonan bab diagnosis lan pamantauan obat.
Antitrombin sing suda bisa nyumbang marang resistensi heparin sing katon, nanging kabutuhan dosis sing ora dikira-kira dhuwure ora mbuktekake defisiensi turunan. Sajrone 1 episode penyakit abot, faktor VIII utawa fibrinogen sing mundhak bisa nyepetake gambaran antikoagulasi adhedhasar aPTT sanajan pajanan heparin wis cukup, mula klinisi bisa ngevaluasi maneh cara pemantauan tinimbang mung nambah dosis perawatan.
Sawetara tes anti-Xa heparin nambah antitrombin eksogen lan liyane ora; prabédan iki bisa mengaruhi apa sing diterangake asil babagan konsentrasi heparin dibandhingake karo aktivitasé ing awak pasien. Takonana laboratorium babagan 2 cara sing kapisah—tes aktivitas antitrombin lan tes pemantauan heparin—amarga cara loro kasebut nangani antitrombin lan heparin durung mesthi padha.
Trombosit sing mudhun luwih saka 50% nalika kena heparin nuwuhake kemungkinan liya, trombositopenia sing dipicu heparin, sing ora didiagnosis adhedhasar antitrombin sing kurang. Panjelasan kita babagan tes PF4 lan penilaian HIT nerangake prabédan kasebut; keputusan babagan ngganti heparin, nggunakake antitrombin pengganti utawa gawe jadwal tes ulang kudu ditetepake tim sing nambani, dudu kanthi mandhegake obat dhewe.
Kepriyé penyakit abot lan DIC nyuda antitrombin?
Sepsis, koagulasi intravaskular diseminata lan stres fisiologis abot bisa nyuda antitrombin liwat panggunaan, gangguan produksi lan distribusi sing owah. Asil sing cetha kurang—contone, 35%—nalika nandhang penyakit kritis asring minangka temuan sing dipikolehi; asil kasebut ora bisa digunakake dhewe kanggo nyebut wong nandhang defisiensi antitrombin turunan sing suwene urip.
DIC dinilai saka pola, dudu 1 protein abnormal: trombosit sing mudhun, PT sing luwih dawa, panandha sing ana gandhengane karo fibrin sing mundhak lan kadhangkala fibrinogen sing suda menehi konteks sing cocog. Fibrinogen bisa tetep normal utawa mundhak ing wiwitan amarga kalebu protein fase akut, mula konsentrasi fibrinogen sing tetep ora otomatis nyingkirake kemungkinan konsumsi sing terus berkembang.
Ing conto hipotetis, aktivitas 38%, trombosit 72 × 10^9/L lan PT sing saya parah nalika nandhang penyakit sistemik abot nuduhake gangguan koagulasi sing dipikolehi tinimbang temuan turunan sing ora ana gandhengane karo liyane. Panjelasan pola laboratorium DIC kita nuduhake sebabé tren saka sawetara pangukuran luwih migunani tinimbang bola-bali mriksa antitrombin nalika penyakit isih aktif.
Perawatan konsentrat antitrombin utawa plasma sing anyar ditindakake bisa ningkatake aktivitas sing diukur lan nutupi tingkat dhasar sing saktenané, nambah sumber ketidakpastian kapindho sajrone rawat inap sing padha. Asil 105% sawise terapi pengganti ora nyingkirake defisiensi turunan, kaya 35% sadurunge pulih uga ora mbuktekake; cathet produk lan wektu pamenehake sadurunge napsirake salah siji persentase.
Apa kelangan protein liwat ginjel bisa nyebabaké aktivitas antitrombin kurang?
Ilange protein sing akeh liwat cipratan bisa nyumbang marang suda antitrombin sing dipikolehi, mligine ing sindrom nefrotik. Proteinuria tingkat nefrotik ing wong diwasa miturut pakulinan paling ora 3.5 g saben 24 jam; klinisi napsirake antitrombin bebarengan karo protein cipratan, albumin serum lan gangguan ginjel sing ndasari, tinimbang mung ngandelake kreatinin utawa eGFR.
eGFR normal ora nyingkirake bocore protein sing gedhe liwat sawar filtrasi glomerular. Contone, wong diwasa kanthi eGFR 95 mL/min/1.73 m², albumin 22 g/L lan protein cipratan 6 g saben dina bisa uga nduweni panjelasan sing kuwat amarga kondisi sing dipikolehi tumrap aktivitas sing kurang, sanajan asil filtrasi katon ngyakinake; kondisi sing tetep urin umpluk lan tes protein pantes ditaksir ing konteks kasebut.
Sesambungan antarane sindrom nefrotik, tingkat antitrombin lan risiko pembekuan getih ora mesthi padha: ora saben wong sing nandhang sindrom nefrotik nduweni antitrombin sing kurang, lan kecenderungan trombosis nglibatake luwih akeh tinimbang ilange 1 protein liwat cipratan. Diagnosis sing ndasari iku penting, kalebu nefropati membranosa, ing ngendi asil PLA2R lan pemantauan ginjel mbantu nerangake proses gangguan ginjel, dudu mbuktekake kelainan pembekuan getih turunan.
Kantesti minangka platform interpretasi hasil tes getih AI sing bisa nyusun persentase antitrombin bebarengan karo albumin lan panandha ginjel, nanging ora bisa nyimpulake jumlah protein ing cipratan mung saka eGFR. Yen aktivitas tetep 62% nalika ilange protein akeh terus, tes ulang isih bisa nggambarake kondisi sing dipikolehi; penilaian turunan sing luwih cetha biasane ditindakake sawise kondisi klinis stabil lan panjelasan saingan kasebut membaik.
Apa penyakit ati utawa perawatan liya bisa nyuda antitrombin?
Reduced liver synthesis can lower antithrombin, especially in advanced liver disease, while certain treatments such as L-asparaginase can also cause acquired reductions. An activity of 55% alongside other abnormalities requires review of protein production, protein loss and treatment history before clinicians consider a genetic explanation.
ALT and AST reflect injury more than protein-making capacity, so normal or mildly elevated enzymes do not guarantee normal antithrombin production. If activity is 57%, albumin is 25 g/L and INR is 1.6, impaired synthesis becomes a possibility—but warfarin, nutrition and protein loss can confound that pattern, as our interpretasi tes ati nerangake.
Albumin cannot serve as a substitute antithrombin test because the 2 proteins have different turnover and can respond differently to illness or therapy. Our albumin and serum protein guide helps interpret the surrounding panel; a normal albumin does not exclude inherited antithrombin deficiency, and a low albumin does not prove that the liver caused it.
L-asparaginase can reduce anticoagulant proteins during cancer treatment, creating an acquired thrombosis risk that may need active management rather than merely a future repeat test. Major procedures, extracorporeal support and recent replacement products can also complicate 1 measurement; eating more protein or taking a vitamin supplement does not correct a SERPINC1-related defect or replace treatment of the underlying acquired cause.
Antikoagulan endi sing ngganggu tes antitrombin?
Direct oral anticoagulants can falsely increase antithrombin activity, potentially masking deficiency rather than causing a low flag. Apixaban, rivaroxaban and edoxaban interfere with factor Xa-based activity assays, while dabigatran can interfere with thrombin-based assays; the same patient’s 2 results may therefore differ because of assay design.
The mechanism is straightforward: the medication inhibits the assay’s added enzyme, and the instrument can misread that inhibition as stronger antithrombin function. The ISTH communication explicitly identifies these drug–assay combinations, including effects from direct thrombin inhibitors such as argatroban and bivalirudin (Van Cott et al., 2020); antigen testing usually avoids this particular functional interference, but does not replace an activity assessment.
A hypothetical activity of 108% on a factor Xa-based assay while taking rivaroxaban may conceal an underlying reduction; activity of 66% on that same drug still cannot be mathematically corrected into a true baseline. Anticoagulants also affect lupus anticoagulant test interpretation, but the direction and mechanism of interference are test-specific, not a universal rule for all thrombophilia assays.
Kantesti AI should support medication-aware interpretation rather than claim that 1 uploaded report identifies the laboratory’s reagent or removes a drug effect. Depending on the situation, the laboratory may use a less-affected assay, measure drug exposure or apply a validated removal procedure; our validasi teknis lan pengawasan describes the broader standards behind interpretation, not a guarantee that AI can resolve missing assay information.
Apa penanganan sampel bisa njelasaké asil kurang sing ora dikira-kira?
Sample quality and assay differences can make antithrombin results unreliable, especially when the laboratory flags collection or processing problems. Coagulation samples typically require a 9:1 ratio of sample to citrate anticoagulant; underfilling, inappropriate handling or an unsuitable specimen should be considered before interpreting an isolated abnormal percentage.
A hematocrit above approximately 55% may require citrate adjustment for coagulation testing because the amount of plasma relative to citrate is reduced. This is a laboratory preparation issue, not evidence of hereditary deficiency; if activity is 73% in a flagged specimen, ask whether the laboratory accepted the sample as valid and whether recollection is preferable to repeating the same material.
Hemolysis, lipemia and marked discoloration can interfere with optical methods, although the effect depends on the instrument and reagent rather than having 1 predictable direction. Our guides to hemolysis-related result distortion lan lipemic specimens and redraws explain why a specimen-quality warning needs a method-specific answer instead of an automatic diagnosis.
Changing laboratories can create a second problem: an activity of 76% by one method and 84% by another may reflect analytical differences rather than biological recovery. Using the same laboratory helps trend comparison, but persistent clinical suspicion may justify a specialist laboratory using an alternative assay that is more sensitive to certain inherited variants; consistency and diagnostic sensitivity are 2 different goals.
Kapan aktivitas antitrombin sing kurang kudu dites manèh?
Repeat antithrombin testing should occur after temporary causes have settled and medication effects have been addressed. Following an acute clot, the BSH recommendation is to wait until after 3 months of anticoagulation before testing natural anticoagulant deficiencies; the safest collection date then depends on the drug, assay and clinical situation.
An incidental borderline result in a well adult without a recent clot does not automatically require the same 3-month wait, because that interval addresses acute thrombosis. The clinician may instead arrange a separate repeat once collection issues and acquired causes are reviewed, adding antigen testing if activity remains low; there is no universally validated waiting interval that fits every outpatient finding.
Heparin-related reductions may recover after treatment ends, but laboratory policies and ongoing illness affect when a repeat becomes meaningful. For a DOAC, a fixed 48-hour pause is not universally adequate or safe: kidney function, dose timing, drug accumulation and assay sensitivity matter, and choosing a compatible method may avoid interrupting treatment entirely.
Kantesti’s trend tools can help organize 2 measurements with their dates, but a timeline should also record clot onset, heparin exposure, the last relevant medication dose and any replacement products. Our explanation of asil sawise metu saka rumah sakit supports that workflow; warfarin does not usually lower antithrombin as it lowers vitamin K-dependent proteins, so protein C or S stopping rules should not be copied automatically.
Temuan apa sing ndhukung defisiensi antitrombin bawaan?
Inherited antithrombin deficiency becomes more likely when activity remains low on separate, interpretable samples, acquired causes are excluded and the personal or family history fits. Two concordant results provide stronger evidence than 1 result during illness, but activity, antigen and sometimes SERPINC1 testing must still be considered together.
A clearly hypothetical profile of activity 54% and 56% on 2 suitable occasions, antigen 51%, no major protein loss and a first-degree relative with confirmed deficiency would support a quantitative inherited pattern. Early or recurrent venous thrombosis increases suspicion, but age alone is not diagnostic, and absence of a family history does not exclude a new variant or previously unrecognized disease.
SERPINC1 testing can help establish a molecular explanation when the laboratory phenotype is convincing and the result could affect management or family counseling. A variant of uncertain significance is not equivalent to a diagnosis, while a negative genetic test does not necessarily exclude every relevant change; the ISTH recommendations also note that molecular testing may identify defects missed by activity assays (Van Cott et al., 2020).
Antithrombin and protein S deficiency require different interpretive rules, even when they appear on the same thrombophilia panel. Our guide to low protein S activity explains several contrasting confounders; a type II antithrombin heparin-binding-site variant can also have a different risk profile from type I deficiency, so 1 generic risk estimate should not be applied to all confirmed variants.
Kapan evaluasi kulawarga cocog ditindakake?
Family evaluation is usually considered after the original patient’s inherited deficiency is convincingly confirmed, especially when the result could change prevention, hormone choices or pregnancy planning. Most inherited antithrombin deficiency is autosomal dominant, giving each child of a heterozygous carrier a 50% chance of inheriting the relevant variant—not a certainty of thrombosis.
The BSH guideline discourages routine thrombophilia testing of all first-degree relatives but supports selective evaluation for relatives of people with antithrombin, protein C or protein S deficiency when results could influence management (Arachchillage et al., 2022). Our pandhuan tes kulawarga adhedhasar risiko explains why testing 1 relevant inherited condition can be more useful than ordering a broad panel without a clinical question.
ASH’s 2023 thrombophilia guideline similarly supports selective testing in certain families with known high-risk deficiencies, including decisions about estrogen exposure and prophylaxis during particular risk situations (Middeldorp et al., 2023). Many recommendations are conditional and based on very low-certainty evidence; antithrombin deficiency should not be treated as interchangeable with factor V Leiden results, which often carry a different risk profile.
Kantesti’s Family Health Risk feature can help organize information shared with consent, but it cannot determine whether a relative inherited a SERPINC1 variant from 1 family member’s activity percentage. Testing children requires age-aware laboratory interpretation and an assessment of whether the result would change care now; predictive testing also deserves counseling about privacy, uncertainty and the difference between inherited susceptibility and an actual clot.
Apa sing kudu dicakup ing rencana tindak lanjut lan pamriksan sumber?
Bring the original percentage, reference interval, medication list and sampling date to follow-up, along with details of the clot, illness or protein loss that could explain the result. Two decisions come first: whether the current finding needs clinical action and whether repeat testing would genuinely change treatment or family counseling.
A low activity percentage alone does not automatically require lifelong anticoagulation or antithrombin concentrate; treatment depends on previous thrombosis, the provoking circumstances, bleeding risk and the confirmed diagnosis. New one-sided leg swelling needs prompt assessment, while sudden shortness of breath, chest pain or fainting requires emergency care even if the last activity was 100%—do not wait for a repeat thrombophilia panel.
Kantesti is an AI lab test interpretation service that can help organize the 2-stage workflow of context review followed by clinician-directed confirmation, not replace hematology advice or authorize medication interruption. Our AI sing tanggung jawab describe that boundary; use AI explanations to prepare precise questions, including which enzyme the assay uses and whether activity and antigen should be collected together.
The clinical recommendations here draw on 3 directly relevant external sources: the ISTH laboratory communication, the BSH testing guideline and the ASH thrombophilia guideline. The 2 Zenodo publications below provide background on serum proteins and immune-related laboratory context—not clinical trials validating antithrombin diagnosis; our standar konten medis lan pemeriksaan komplemen lan otoimun help readers distinguish supporting education from condition-specific evidence.
Pitakon sing kerep ditakoni
Apa aktivitas antitrombin sing kurang mesthi ateges defisiensi turun-temurun?
0 Aktivitas antitrombin sing rendah ora mesthi ateges kekurangan bawaan. Aktivitas 60% bisa kedadeyan nalika trombosis akut, perawatan heparin, penyakit parah, penyakit ati tahap lanjut utawa ilange protein akeh liwat urin. Klinisi nggoleki penurunan sing tetep ing sampel-sampel kapisah kanthi wektu pengambilan sing cocog sawise mriksa panjelasan sing diduweni iki. Tes antigen lan kadhangkala tes SERPINC1 mbantu nggolongake kelainan sing wis dikonfirmasi.
Kapan tes aktivitas antitrombin kudu diulang sawisé dumadi gumpalan getih?
0 Sawisé ana bekuan getih akut, British Society for Haematology nyaranaké supaya kekurangan antikoagulan alami dites mung sawisé 3 wulan nampa terapi antikoagulasi. Rencana pengambilan sampel sing nyata uga kudu nggatekaké wektu pemulihan, antikoagulan sing digunakaké, lan pamriksan laboratorium. Rekomendasi iki ora ateges saben wong kudu mandheg ngonsumsi obat sawisé 3 wulan. Aja pisan-pisan ngendhegaké terapi antikoagulasi kanggo tes tanpa instruksi saka klinisi sing menehi resep.
Apa bedane antithrombin antigen lan aktivitas?
0. Aktivitas antitrombin ngukur fungsi, dene antigen antitrombin ngukur jumlah protein. Defisiensi jinis I umume nyuda asil loro-lorone; defisiensi jinis II umume nyuda aktivitas sanajan antigen relatif normal. Contone, aktivitas sing diulang 52% kanthi antigen 101% nuduhake pola kualitatif, nanging ora netepake panyebab keturunan tanpa mriksa kondisi sing dipikolehi lan efek obat. Tes antigen ora bisa ngganteni penilaian fungsi sing valid.
Apa apixaban utawa rivaroxaban bisa mengaruhi asil antitrombin?
Apixaban lan rivaroxaban bisa nambah aktivitas antitrombin kanthi palsu ing tes adhedhasar faktor Xa, sing bisa ndhelikake defisiensi. Dabigatran uga bisa nambah aktivitas sing katon ing tes adhedhasar trombin. Mula, asil 100% nalika ngonsumsi obat sing ngganggu bisa uga ora sakayakin katon. Laboratorium bisa milih metode sing kurang kena pengaruh utawa strategi tervalidasi liyane; mandheg ngonsumsi obat dhewe iku ora aman.
Apa aktivitas antitrombin 70% mbebayani?
Aktivitas antitrombin 70% luwih cendhek tinimbang akeh interval referensi laboratorium kanggo wong diwasa, nanging persentase kasebut waé ora mesthi nuduhake kahanan darurat utawa ngukur risiko bekuan getih pribadi. Maknane gumantung marang tes, obat-obatan, riwayat bekuan getih sadurunge, riwayat kulawarga lan penyakit sing saiki dialami. Asil tunggal biasane perlu ditinjau sacara klinis lan direncanakake konfirmasi sing trep. Ambegan dadakan dadi sesak, nyeri dada, semaput utawa sikil siji anyar abuh mbutuhake pemeriksaan, ora gumantung marang persentase kasebut.
Apa kulawargaku kudu dites yen aku kekurangan antitrombin?
Турана kulawarga kanthi pilihan bisa cocog sawisé kekurangan antitrombin warisan dikonfirmasi kanthi yakin, utamané nalika asilé bakal ngowahi pencegahan, pilihan hormon utawa perencanaan meteng. Pembawa heterozigot umume duwé kemungkinan 50% kanggo nurunaké varian sing ana gandhèngané marang saben anak, nanging iki dudu kepastian 50% yèn anak kasebut bakal ngalami trombosis. Pandhuan BSH lan ASH ndhukung evaluasi adhedhasar kaputusan, dudu tes sembarangan kanggo saben sedulur. Anak-anak mbutuhaké interpretasi sing cocog karo umur lan rembugan bab apa tes bakal ngowahi perawatan saiki.
Entuk penjelasan babagan asil tes getih sampeyan
Unggah laporan laboratorium sampeyan lan AI Kantesti bakal nerangake saben biomarker nganggo basa sing prasaja sajrone sawetara detik. Digunakake luwih saka 2 yuta wong ing saindenging donya.
Referensi
- Klein, T., Mitchell, S., & Weber, H. (2026). Pandhuan Protein Serum: Globulin, Albumin & Rasio A/G ing Tes Getih. Riset Medis AI Kantesti. DOI
- Klein, T., Mitchell, S., & Weber, H. (2026). Pandhuan Tes Getih C3 C4 Komplemen & Titer ANA. Riset Medis AI Kantesti. DOI
- Van Cott EM et al. (2020). Recommendations for clinical laboratory testing for antithrombin deficiency; Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. DOI
- Arachchillage DJ et al. (2022). Pangujian trombofilia: Pedoman British Society for Haematology. British Journal of Haematology. DOI
- Middeldorp S et al. (2023). Pedoman American Society of Hematology 2023 kanggo penanganan tromboembolisme vena: pangujian trombofilia. Blood Advances. DOI
- 2M+Tes sing dianalisis
- 127+negara-negara
- 100+Basa
Babagan tim medis
Sinyal Kepercayaan E-E-A-T
Pengalaman
Tinjauan klinis sing dipimpin dokter babagan alur kerja interpretasi lab.
Keahlian
Fokus kedokteran laboratorium babagan carane biomarker tumindak ing konteks klinis.
Kewibawaan
Ditinjau sacara medis dening Dr. Thomas Klein, kanthi kontribusi saka Dr. Sarah Mitchell lan Prof. Dr. Hans Weber.
Kapercayan
Interpretasi adhedhasar bukti kanthi tindak lanjut sing cetha kanggo nyuda rasa kaget.
Sanggahan medis
Artikel iki mung kanggo tujuan edukasi lan ora dadi saran medis. Tansah konsultasi karo panyedhiya layanan kesehatan sing mumpuni kanggo keputusan diagnosis lan perawatan.
Diterbitake · Hubungi tim editorial
Diterbitake dening Kantesti Ltd, kadhaptar ing Inggris & Wales, nomer perusahaan. 17090423, London, Britania Raya.
